Team:MIT
From 2014.igem.org
Shinjini37 (Talk | contribs) |
|||
(55 intermediate revisions not shown) | |||
Line 17: | Line 17: | ||
<br> | <br> | ||
<table width=95% align=center> | <table width=95% align=center> | ||
- | <tr><td><h3 style="font-size:20px" align=center> | + | |
- | <tr><td><h3 style="font-size:50px" align=center>ALZHEIMER'S DISEASE</h3></td></tr> | + | <tr><td><h3 style="font-size:20px; color:teal" align=center><b>IMPROVING THE DIAGNOSIS AND TREATMENT OF</u></h3></td></tr> |
+ | <tr><td><h3 style="font-size:50px; color:teal" align=center><b>ALZHEIMER'S DISEASE</b></h3></td></tr> | ||
<tr><td><h3 style="font-size:25px" align=right><br></h3></td></tr> | <tr><td><h3 style="font-size:25px" align=right><br></h3></td></tr> | ||
+ | |||
+ | |||
<table width=95% align=center> | <table width=95% align=center> | ||
Line 28: | Line 31: | ||
</tr> | </tr> | ||
<tr> | <tr> | ||
- | <td width=33.3%><p style="font-size: | + | <td width=33.3%><p style="font-size:12px; color:teal" align=top><b> NEURODEGENERATIVE <br>DISEASE </b></p></td> |
- | <td width=33.3%><p style="font-size: | + | <td width=33.3%><p style="font-size:12px; color:teal"><b> 6th LEADING CAUSE OF<br> DEATH IN THE U.S.</b></p></td> |
- | <td width=33.3%><p style="font-size: | + | <td width=33.3%><p style="font-size:12px; color:teal"><b> CURRENT DIAGNOSTICS AND<br> THERAPEUTICS ARE INEFFECTIVE</b></p></td> |
</tr> | </tr> | ||
</table> | </table> | ||
+ | <br><br> | ||
<table width=90% align=center> | <table width=90% align=center> | ||
<tr><td><br><p style="font-size:15px" align=left><b>Alzheimer's disease is the sixth leading cause of death</b> in the United States, affecting more than 5 million Americans and resulting in the deaths of 500,000 people every year (Alzheimer's Association). Though one in three seniors dies with this disease (Alzheimer's Association), it currently has no cure, and, according to the clinicians that we interviewed, existing diagnosis methods are unreliable. <b>MIT iGEM 2014 is working to change this situation.</b> We set out to devise a way to diagnose Alzheimer's disease using biological rather than psychological tests and to invent a treatment mechanism that would capitalize on recent findings about the molecular pathology of the disease. Using the principles of synthetic biology, we designed a system that <b>detects molecular biomarkers</b> for Alzheimer's disease and <b>alters the levels of key enzymes</b> in response. Our dynamic system combats Alzheimer's disease only when the disease is detected, providing a specific, state-sensitive treatment. In the future, an approach like ours could provide a solution for patients suffering from the debilitating effects of Alzheimer's disease and improve the lives of their caretakers and family. | <tr><td><br><p style="font-size:15px" align=left><b>Alzheimer's disease is the sixth leading cause of death</b> in the United States, affecting more than 5 million Americans and resulting in the deaths of 500,000 people every year (Alzheimer's Association). Though one in three seniors dies with this disease (Alzheimer's Association), it currently has no cure, and, according to the clinicians that we interviewed, existing diagnosis methods are unreliable. <b>MIT iGEM 2014 is working to change this situation.</b> We set out to devise a way to diagnose Alzheimer's disease using biological rather than psychological tests and to invent a treatment mechanism that would capitalize on recent findings about the molecular pathology of the disease. Using the principles of synthetic biology, we designed a system that <b>detects molecular biomarkers</b> for Alzheimer's disease and <b>alters the levels of key enzymes</b> in response. Our dynamic system combats Alzheimer's disease only when the disease is detected, providing a specific, state-sensitive treatment. In the future, an approach like ours could provide a solution for patients suffering from the debilitating effects of Alzheimer's disease and improve the lives of their caretakers and family. | ||
<br><br> | <br><br> | ||
- | |||
- | |||
</table> | </table> | ||
<br><br> | <br><br> | ||
<table width=95% align=center> | <table width=95% align=center> | ||
- | <tr><td colspan=3><h3 style="font-size:25px">DETECTION</h3></td> | + | <tr><td colspan=3><h3 style="font-size:25px; color:teal">DETECTION</h3></td> |
</tr> | </tr> | ||
<tr> | <tr> | ||
+ | <br><br> | ||
<td width=33.3%><a href="https://2014.igem.org/Team:MIT/Protein_sensor"><img src="https://static.igem.org/mediawiki/2014/e/e9/MIT_Native_receptor_homepage.png"><br><p style="font-size:12px; color:black"><b>NATIVE β-AMYLOID RECEPTOR</b></p></a></td> | <td width=33.3%><a href="https://2014.igem.org/Team:MIT/Protein_sensor"><img src="https://static.igem.org/mediawiki/2014/e/e9/MIT_Native_receptor_homepage.png"><br><p style="font-size:12px; color:black"><b>NATIVE β-AMYLOID RECEPTOR</b></p></a></td> | ||
<td width=33.3%><a href="https://2014.igem.org/Team:MIT/BCR"><img src="https://static.igem.org/mediawiki/2014/f/f8/MIT_bcr_homepage.png"><br><p style="font-size:12px; color:black"><b>ENGINEERED B-CELL RECEPTOR</b></p></a></td> | <td width=33.3%><a href="https://2014.igem.org/Team:MIT/BCR"><img src="https://static.igem.org/mediawiki/2014/f/f8/MIT_bcr_homepage.png"><br><p style="font-size:12px; color:black"><b>ENGINEERED B-CELL RECEPTOR</b></p></a></td> | ||
- | <td width=33.3%><a href="https://2014.igem.org/Team:MIT/miRNA"><img src="https://static.igem.org/mediawiki/2014/8/88/MIT_mirna_homepage.png"><br><p style="font-size:12px; color:black"><b>miRNA | + | <td width=33.3%><a href="https://2014.igem.org/Team:MIT/miRNA"><img src="https://static.igem.org/mediawiki/2014/8/88/MIT_mirna_homepage.png"><br><p style="font-size:12px; color:black"><b>miRNA DETECTION</b></p></a></td> |
<tr> | <tr> | ||
</table> | </table> | ||
- | |||
- | |||
- | |||
- | |||
- | |||
<br><br> | <br><br> | ||
+ | <table width=74.5% align=center> | ||
+ | <tr><td><h3 style="font-size:23.5px; color:teal">TREATMENT</h3></td> | ||
+ | <td><h3 style="font-size:23.5px; color:teal">DELIVERY</h3></td> | ||
+ | </tr> | ||
<tr> | <tr> | ||
<td width=50%><a href="https://2014.igem.org/Team:MIT/Treatment"><img src="https://static.igem.org/mediawiki/2014/1/19/MIT_treatment_homepage.png"></a></td> | <td width=50%><a href="https://2014.igem.org/Team:MIT/Treatment"><img src="https://static.igem.org/mediawiki/2014/1/19/MIT_treatment_homepage.png"></a></td> | ||
<td width=50%><a href="https://2014.igem.org/Team:MIT/Delivery"><img src="https://static.igem.org/mediawiki/2014/0/06/MIT_future_homepage.png"></a></td> | <td width=50%><a href="https://2014.igem.org/Team:MIT/Delivery"><img src="https://static.igem.org/mediawiki/2014/0/06/MIT_future_homepage.png"></a></td> | ||
</tr> | </tr> | ||
- | <tr><td><a href="https://2014.igem.org/Team:MIT/Treatment"><p style="font-size:12px; color:black"><b>REGULATING β-AMYLOID PRODUCTION | + | <tr><td><a href="https://2014.igem.org/Team:MIT/Treatment"><p style="font-size:12px; color:black"><b>REGULATING β-AMYLOID PRODUCTION<br>AND DEGRADATION</b></p></a></td> |
<td><a href="https://2014.igem.org/Team:MIT/Delivery"><p style="font-size:12px; color:black"><b>DELIVERING THE CIRCUIT</b></p></a></td> | <td><a href="https://2014.igem.org/Team:MIT/Delivery"><p style="font-size:12px; color:black"><b>DELIVERING THE CIRCUIT</b></p></a></td> | ||
</tr> | </tr> | ||
</table> | </table> | ||
<br> | <br> | ||
- | + | <tr><td><p style="font-size:12px" align=center><i>Attributions: Kathryn Brink, Alexa Garcia, Shinjini Saha<br>Kathryn Brink (Content), Alexa Garcia (Content), Shinjini Saha (Illustrations)<br> Special mention: Shinjini Saha (Illustrations for entire website)</i></p></td></tr> | |
</body> | </body> | ||
</table> | </table> |
Latest revision as of 03:54, 18 October 2014
Home | Our Project | Lab Work | Outreach | About Us | Medals |
IMPROVING THE DIAGNOSIS AND TREATMENT OF | ||
ALZHEIMER'S DISEASE | ||
NEURODEGENERATIVE |
6th LEADING CAUSE OF |
CURRENT DIAGNOSTICS AND |
Alzheimer's disease is the sixth leading cause of death in the United States, affecting more than 5 million Americans and resulting in the deaths of 500,000 people every year (Alzheimer's Association). Though one in three seniors dies with this disease (Alzheimer's Association), it currently has no cure, and, according to the clinicians that we interviewed, existing diagnosis methods are unreliable. MIT iGEM 2014 is working to change this situation. We set out to devise a way to diagnose Alzheimer's disease using biological rather than psychological tests and to invent a treatment mechanism that would capitalize on recent findings about the molecular pathology of the disease. Using the principles of synthetic biology, we designed a system that detects molecular biomarkers for Alzheimer's disease and alters the levels of key enzymes in response. Our dynamic system combats Alzheimer's disease only when the disease is detected, providing a specific, state-sensitive treatment. In the future, an approach like ours could provide a solution for patients suffering from the debilitating effects of Alzheimer's disease and improve the lives of their caretakers and family.
|
DETECTION |
||
NATIVE β-AMYLOID RECEPTOR |
ENGINEERED B-CELL RECEPTOR |
miRNA DETECTION |
TREATMENT |
DELIVERY |
REGULATING β-AMYLOID PRODUCTION |
DELIVERING THE CIRCUIT |
Attributions: Kathryn Brink, Alexa Garcia, Shinjini Saha
Kathryn Brink (Content), Alexa Garcia (Content), Shinjini Saha (Illustrations)
Special mention: Shinjini Saha (Illustrations for entire website)